Biotech | August 11, 2021
Moderna to set up mRNA manufacturing in Canada
The collaboration will support Canada with direct access to rapid pandemic response capabilities
The collaboration will support Canada with direct access to rapid pandemic response capabilities
TSC causes epilepsy in up to 85 % of patients, and up to 60 % of those patients do not respond to standard anti-seizure medicines
Company working on COVID vaccine INO 4800
Preclinical and early human data indicate BriLife may confer enhanced immunity against Delta variant
Filing for WHO Emergency Use Authorisation this month
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells
Deal for 100 million doses with additional 100 million through 2023
The TWYMEEG approval is supported by numerous preclinical and clinical studies, including the Phase 3 TIMES (Trials of IMeglimin for Efficacy and Safety) program managed jointly by both the companies
Allecra Therapeutics would now either directly or through out license file for NDA of this molecule.
Subscribe To Our Newsletter & Stay Updated
